

Date: September 26, 2024

To,  
The Corporate Relations Department,  
**BSE Limited,**  
Phiroze Jeebhoy Towers,  
Dalal Street, Mumbai - 400 001

**Oxygenta Pharmaceutical Limited**  
Survey No.252/1, Aroor village,  
Sadasivapet mandal,  
Medak District-502291, Telangana.

Dear Sir/ Madam,

**Sub: Disclosure under Regulation 29(2) and 29(3) of the SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011.**

**Ref: BSE Scrip Code: 524636**


In compliance with the disclosure requirements set out under Regulation 29(2) read with Regulation 29(3) of the Securities and Exchange Board of India (Substantial Acquisition of Shares and Takeovers) Regulations, 2011, please find enclosed herewith the disclosure pursuant to requirement of Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 as **Annexure-I** for sale of 69,52,600 (19.59%) equity shares of the Oxygenta Pharmaceutical Limited on September 24, 2024.

This is for your information and necessary records.

Thanking You,

Yours Faithfully,

**For and on behalf of Promoter and PACs**



---

**M V S Prasad Reddy**  
Promoter

Place: Hyderabad  
Date: 26/09/2024

**Annexure-I**

**Disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011**

Name of the Target Company (TC) Oxygenta Pharmaceutical Limited

Name of the acquirer and Persons Acting in Concert (PAC) M V S Prasad Reddy

Persons Acting in Concert (PAC):

1. Amigos Molecular Solutions Private Limited

2. Aparna Rachamalla

Whether the Acquirer belongs to the Promoter / Promoter group Yes

Name(s) of the Stock Exchange where the shares of the TC Listed BSE Limited

Details of the acquisition / disposal as follows	Number	% w.r.t. total share/voting capital Wherever applicable	% w.r.t. total diluted share/voting capital of the TC
<b>Before the acquisition/sale under consideration, holding of:</b>			
a) Shares carrying voting rights *	20,00,302	5.64	5.64
b) Shares in the nature of encumbrance (pledge/ lien/ non-disposal undertaking/ others)	Nil	Nil	Nil
c) Voting rights (VR) otherwise than by shares	Nil	Nil	Nil
d) Warrants/convertible securities/any other instrument that entitles the acquirer to receive shares carrying voting rights in the TC (specify holding in each category)	Nil	Nil	Nil
<b>e) Total (a+b+c+d)</b>	<b>20,00,302</b>	<b>5.78</b>	<b>5.78</b>
<b>Details of acquisition/sale</b>			
a) Shares carrying voting rights <del>acquired</del> /sold	69,52,600	19.59	19.59
b) VRs <del>acquired</del> /sold otherwise than by shares	Nil	Nil	Nil
c) Warrants/convertible securities/any other instrument that entitles the acquirer to receive shares carrying voting rights in the TC (specify holding in each category)	Nil	Nil	Nil
d) Shares encumbered/invoked/released by the acquirer	Nil	Nil	Nil
<b>e) Total (a+b+c+/-d)</b>	<b>69,52,600</b>	<b>19.59</b>	<b>19.59</b>
<b>After the acquisition/sale, holding of:</b>			
a) Shares carrying voting rights <del>acquired</del> /sold	89,52,902	25.23	25.23
b) Shares encumbered with the acquirer	Nil	Nil	Nil
c) VRs otherwise than by shares	Nil	Nil	Nil
d) Warrants/convertible securities/any other instrument that entitles the acquirer to receive shares carrying voting rights in the TC (specify holding in each category) after	Nil	Nil	Nil

acquisition

e) Total (a+b+c+d)

89,52,902 25.23

25.23

Mode of ~~acquisition~~/ sale (e.g. open market/ off-market/  
off-market/ public issue/ rights issue/  
preferential allotment/ inter-se transfer etc.,)

Date of ~~acquisition~~ / sale of shares / ~~VR or~~ September 24, 2024  
~~date of receipt of intimation of allotment of~~  
~~shares, whichever is applicable~~

Equity share capital / total voting capital of 3,54,83,500 equity shares of Rs. 10/- each  
the TC before the said acquisition / sale amounting to Rs. 35,48,35,000/-

Equity share capital/ total voting capital of 3,54,83,500 equity shares of Rs. 10/- each  
the TC after the said acquisition / sale amounting to Rs. 35,48,35,000/-

Total diluted shares/voting capital of the TC 3,54,83,500 equity shares of Rs. 10/- each  
after the said acquisition amounting to Rs. 35,48,35,000/-

Note:

\* The 20,00,302 Equity shares mentioned in the before the acquisition holding of equity shares, in which 17,00,000 equity shares were allotted to MVS Prasad Reddy, 2,00,000 Equity shares allotted to Amigos Molecular Solutions Private Limited and 1,00,000 equity shares allotted to Aparna Rachamalla on Preferential issue basis on 21<sup>st</sup> May 2024 and these share are kept in Oxygenta Pharmaceutical Limited Open Offer Escrow Demat Account 2024 in terms of Regulation 22(2A) of the SEBI (SAST) Regulations,2011 and the remaining 302 equity shares were acquired by MVS Prasad Reddy in the open offer.

**For and on behalf of Promoter and PACs**



---

**M V S Prasad Reddy**  
**Promoter**

Place: Hyderabad

Date: 26/09/2024